Methyl rosmarinate

Methyl rosmarinate 是一种具有口服活性的羟基肉桂酸,对 PTP1B 的 IC50 为 24.70 μM、Ki 为 15.29 μM,对 BChE 的 IC50 为 41.46 μg/mL,对蘑菇酪氨酸酶 (mushroom tyrosinase) 的 Ki 为 0.61 mM,对 SARS-CoV-2 3CLpro 的 IC50 为 2.50 μM,可下调 ERK、JNK、p38、Smad2、Smad3 的磷酸化水平,激活红细胞 BPGM 并促进 2,3-BPG 生成,诱导成纤维细胞凋亡 (apoptosis),延长缺氧小鼠的存活时间,提高胰岛素敏感性,结合 SARS-CoV-2 3CLpro 并抑制病毒复制,诱导胶质母细胞瘤死亡,激活 TGR5/AMPK 轴并降低 ROS、MDA 水平,对 MMP-1 有抑制活性,可用于肺纤维化、缺氧诱导损伤、2 型糖尿病、阿尔茨海默病、色素沉着过度疾病、新型冠状病毒肺炎、胶质母细胞瘤及心肌缺血再灌注损伤的相关研究。
产品编号: MS-T38642 纯度: 99.46% CAS No.: 99353-00-1 分子式: C19H18O8 分子量: 374.34
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Methyl rosmarinate 是一种具有口服活性的羟基肉桂酸,对 PTP1B 的 IC50 为 24.70 μM、Ki 为 15.29 μM,对 BChE 的 IC50 为 41.46 μg/mL,对蘑菇酪氨酸酶 (mushroom tyrosinase) 的 Ki 为 0.61 mM,对 SARS-CoV-2 3CLpro 的 IC50 为 2.50 μM,可下调 ERK、JNK、p38、Smad2、Smad3 的磷酸化水平,激活红细胞 BPGM 并促进 2,3-BPG 生成,诱导成纤维细胞凋亡 (apoptosis),延长缺氧小鼠的存活时间,提高胰岛素敏感性,结合 SARS-CoV-2 3CLpro 并抑制病毒复制,诱导胶质母细胞瘤死亡,激活 TGR5/AMPK 轴并降低 ROS、MDA 水平,对 MMP-1 有抑制活性,可用于肺纤维化、缺氧诱导损伤、2 型糖尿病、阿尔茨海默病、色素沉着过度疾病、新型冠状病毒肺炎、胶质母细胞瘤及心肌缺血再灌注损伤的相关研究。

生物实验数据

生物活性 Methyl rosmarinate is an orally active hydroxycinnamic acid that exhibits an IC50 of 24.70 μM and a Ki of 15.29 μM against PTP1B, an IC50 of 41.46 μg/mL against BChE, a Ki of 0.61 mM against mushroom tyrosinase, and an IC50 of 2.50 μM against SARS-CoV-2 3CLpro; it downregulates the phosphorylation levels of ERK, JNK, p38, Smad2, and Smad3, activates erythrocyte BPGM to promote 2,3-BPG production, induces apoptosis in fibroblasts, prolongs the survival time of hypoxic mice, improves insulin sensitivity, binds to SARS-CoV-2 3CLpro to inhibit viral replication, induces glioblastoma cell death, activates the TGR5/AMPK axis to reduce ROS and MDA levels, exhibits inhibitory activity against MMP-1, and can be used in research related to pulmonary fibrosis, hypoxia-induced injury, type 2 diabetes, Alzheimer's disease, hyperpigmentation disorders, coronavirus disease 2019, glioblastoma, and myocardial ischemia-reperfusion injury.
IC50 & Target Tyrosinase:0.28 mM
体外研究
(In Vitro)

Methyl rosmarinate (10-160 μM; 48 h) 对 L929 细胞表现出细胞毒性,IC50 为 76.27 μM。
Methyl rosmarinate (10-40 μM; 48 h) 降低经 TGF-β1 刺激的 L929 细胞中的细胞外基质蛋白积累。
Methyl rosmarinate (20-40 μM; 12-72 h) 抑制 TGF-β1 刺激的小鼠成纤维细胞 L929 的增殖和迁移,提高细胞的凋亡率。
Methyl rosmarinate (20-40 μM; 48 h) 在经 TGF-β1 刺激的小鼠成纤维细胞 L929 中升高促凋亡蛋白 Bax, cleaved caspase 3, and cleaved caspase 9 的表达水平,降低抗凋亡蛋白 Bcl-2 的表达水平,抑制 TGF-β1/Smad 和 MAPK 信号通路的磷酸化,减轻细胞的纤维化反应。
Methyl rosmarinate 可竞争性、可逆性地抑制重组人 PTP1B 酶的活性,其 IC50 为 24.7 μM,Ki 为 15.29 μM。
Methyl rosmarinate (6.25-25 μM; 24 h) 可作为胰岛素增敏剂,增强完全分化的 C2C12 肌管中胰岛素刺激的葡萄糖摄取,增强完全分化的 C2C12 肌管中胰岛素刺激的糖原合成,胰岛素信号通路,提升胰岛素刺激的 IRS-1 和 Akt 磷酸化水平,且不改变 PTP1B 蛋白表达量。
Methyl rosmarinate 可抑制丁酰胆碱酯酶 (BChE),IC50 为 41.46 µg/mL,但对乙酰胆碱酯酶 (AChE) 无显著抑制作用。
Methyl rosmarinate (0.01-0.4 mM; 2 min preincubation, 5 min reaction) 可抑制蘑菇酪氨酸酶的二酚酶活性,Ki 为 0.61 mM,抑制酵母 α-葡萄糖苷酶活性。
Methyl rosmarinate 可作为纯化 SARS-CoV-2 3CLpro 的变构抑制剂,其 IC50 为 2.5 μM,Ki 为 1.27 μM,Kd 为 5.93 μM。
Methyl rosmarinate (1-200 μM; 52 h total) 可抑制 Huh7 细胞中 SARS-CoV-2 复制子的复制,其 EC50 为 18.91 μM,且在 200 μM 浓度下仅表现出中度细胞毒性。
Methyl rosmarinate (5-60 μM; 72 h) 可呈剂量依赖性降低人胶质母细胞瘤 U87 (IC50 = 9.8 μM) 和 T98 (IC50 = 13 μM) 细胞系的活力。
Methyl rosmarinate (9.8-19.6 μM (U87 cells); 13-26 μM (T98 cells); 72 h) 可诱导 U87 细胞发生 subG0 期和 S 期阻滞,诱导 T98 细胞发生 subG0 期和 G2/M 期阻滞。
Methyl rosmarinate (9.8-19.6 μM (U87 cells); 13-26 μM (T98 cells); 48 h) 可剂量依赖性地抑制 U87 和 T98 细胞系的迁移。
Methyl rosmarinate 抑制纯化的人 MMP-1,其 IC50 为 14.7 μM。

Cell Cytotoxicity Assay

Cell Line: mouse fibroblast L929 cells
Concentration: 0, 10, 20, 40, 80, and 160 μM
Incubation Time: 48 h
Result: Exhibited cytotoxicity toward L929 cells, with an IC50 value of 76.27 μM.
Reduced cell viability to 92.53% of the control at 80 μM.
Reduced cell viability to 48.82% of the control at 160 μM.

Western Blot Analysis

Cell Line: TGF-β1-stimulated mouse fibroblast L929 cells
Concentration: 10, 20, 40 μM
Incubation Time: 48 h (following 72 h of TGF-β1 stimulation)
Result: Dose-dependently reduced the elevated expression of collagen-I, collagen-III, vimentin, α-SMA, and snail proteins induced by TGF-β1 stimulation.
Caused significant, concentration-dependent decreases in the expression of all these fibrosis-associated proteins relative to TGF-β1-only treated cells.

Cell Proliferation Assay

Cell Line: TGF-β1-stimulated mouse fibroblast L929 cells
Concentration: 20, 40 μM
Incubation Time: 12, 24, 48, 72 h (co-treated with TGF-β1)
Result: Significantly inhibited the increased proliferation of L929 cells induced by TGF-β1 at all measured time points.
Showed statistically significant inhibitory effects at both 20 μM and 40 μM concentrations relative to TGF-β1-only treated cells.

Cell Migration Assay

Cell Line: TGF-β1-stimulated mouse fibroblast L929 cells
Concentration: 20, 40 μM
Incubation Time: 24, 48 h (following TGF-β1 induction)
Result: Significantly reduced the migration rate of TGF-β1-stimulated L929 cells at both 24 and 48 h.
Showed a stronger inhibitory effect at 40 μM concentration relative to the 20 μM concentration.

Apoptosis Analysis

Cell Line: TGF-β1-stimulated mouse fibroblast L929 cells
Concentration: 20, 40 μM
Incubation Time: 48 h (following TGF-β1 induction)
Result: Significantly increased the apoptosis rate of TGF-β1-stimulated L929 cells.
Increased apoptosis rate to 5.49% at 20 μM relative to 3.53% in TGF-β1-only treated cells.
Increased apoptosis rate to 10.32% at 40 μM relative to 3.53% in TGF-β1-only treated cells.

Western Blot Analysis

Cell Line: TGF-β1-stimulated mouse fibroblast L929 cells
Concentration: 20, 40 μM
Incubation Time: 48 h (following TGF-β1 induction)
Result: Increased expression of pro-apoptotic proteins Bax, cleaved caspase 3, and cleaved caspase 9 in a dose-dependent manner relative to TGF-β1-only treated cells.
Decreased expression of anti-apoptotic protein Bcl-2 in a dose-dependent manner relative to TGF-β1-only treated cells.\nDose-dependently reduced the phosphorylation ratios of p-Smad2/Smad2, p-Smad3/Smad3, p-ERK/ERK, p-JNK/JNK, and p-p38/p38 in TGF-β1-stimulated L929 cells.
Caused statistically significant decreases in phosphorylation ratios at both 20 and 40 μM relative to TGF-β1-only treated cells.

Western Blot Analysis

Cell Line: fully differentiated C2C12 myotubes
Concentration: 6.25, 12.5 and 25 μM
Incubation Time: 24 h
Result: Did not alter PTP1B protein expression.
Dose-dependently enhanced insulin-stimulated phosphorylation of IRS-1 and Akt, with significant increases observed at 12.5 and 25 μM relative to the insulin-only group.

Cell Viability Assay

Cell Line: human glioblastoma U87, T98 cell lines
Concentration: 5, 15, 30, 45, 60 μM
Incubation Time: 72 h
Result: Reduced cell viability in a dose-dependent manner in both cell lines.
Reached a half maximal inhibitory concentration (IC50) of 9.8 μM in U87 cells and 13 μM in T98 cells.
Induced morphological changes including shrinking and death at higher concentrations.

Cell Cycle Analysis

Cell Line: human glioblastoma U87, T98 cell lines
Concentration: 9.8, 19.6 μM (U87 cells); 13, 26 μM (T98 cells)
Incubation Time: 72 h
Result: Increased subG0/G1 phase from 1.9945% to 16.331% and S phase from 7.318% to 15.249% in U87 cells.
Increased subG0/G1 phase from 0.835% to 5.179% and G2/M phase from 4.502 to 16.551 in T98 cells.
Caused statistically significant changes in both cell lines.
体内研究
(In Vivo)

Methyl rosmarinate (20 mg/kg;口服;每日;第 3 天至第 28 天) 可显著减轻 Bleomycin (MS-R86735) 诱导的 C57BL/6 雄性小鼠肺纤维化。
Methyl rosmarinate (25-75 mg/kg,腹腔注射;每日 1 次;连续 3 天,) 可延长常压密闭缺氧小鼠的存活时间,通过降低炎症因子、改善组织氧化应激、缓解组织病理损伤及减轻组织缺氧,保护小鼠免受高海拔野外缺氧的损伤,增强暴露于高海拔野外缺氧环境的小家鼠 (Mus musculus) 红细胞糖酵解通路活性,激活 BPGM,并提升 2,3-BPG 水平,进而改善红细胞的氧释放能力。
Methyl rosmarinate (6.25-25 mg/kg;灌胃;每日;7 周) 可改善高脂饮食/ Streptozotocin (MS-Q80520) 诱导的 2 型糖尿病小鼠的胰岛素敏感性,恢复糖脂稳态,保护骨骼肌与器官功能,并增强 β 细胞功能。
Methyl rosmarinate (50-200 mg/kg;腹腔注射;结扎前 3 小时单次给药) 可通过激活 TGR5/AMPK 信号轴,呈剂量依赖性地改善心肌缺血再灌注损伤模型 Mus musculus (小鼠) 的心功能,减轻其心肌损伤、氧化应激及线粒体损伤。

Animal Model: C57BL/6 (male, bleomycin-induced pulmonary fibrosis model)
Dosage: 20 mg/kg
Administration: p.o.; daily; day 3 to day 28
Result: Significantly improved mouse body weight and reduced lung fibrosis as visualized by small animal MicroCT.
Improved lung structure, reduced inflammatory cell infiltration, and decreased collagen deposition compared to the bleomycin-only group.
Reduced Ashcroft fibrosis score from ~5.2 in the bleomycin-only group to ~1.8.
Reduced collagen deposition area from ~50% in the bleomycin-only group to ~45%.
Significantly reduced lung tissue levels of fibrosis-associated proteins collagen-I and collagen-III compared to the bleomycin-only group.
Animal Model: BALB/c (male and female, 18-22 g)
Dosage: 25 mg/kg; 50 mg/kg; 75 mg/kg
Administration: i.p.; daily; 3 days
Result: Prolonged survival time by 20.15% (31.89 minutes) at 25 mg/kg vs.
blank control.
Prolonged survival time by 24.35% (33.00 minutes) at 50 mg/kg vs.
blank control.
Prolonged survival time by 24.19% (32.96 minutes) at 75 mg/kg vs.
blank control.
Showed statistically significant survival time increases across all dose groups vs.
blank control.
Animal Model: C57BL/6 J (male, 6 weeks old, high-fat diet + streptozotocin-induced type 2 diabetes)
Dosage: 6.25 mg/kg; 25 mg/kg
Administration: i.g.; daily; 7 weeks
Result: Reversed decreased body weight and elevated fasting blood glucose levels, with effects comparable to metformin.
Reduced weekly food intake and decreased glycosylated serum protein (GSP) levels in a dose-dependent manner.
Improved glucose clearance during GTT and insulin sensitivity during ITT, as evidenced by reduced area under the curve (AUC) values compared to vehicle-treated T2D mice.
Increased fasting serum insulin (FINS) levels; the 25 mg/kg dose significantly reduced the homeostasis model assessment of insulin resistance (HOMA-IR) index and improved the homeostasis model assessment of β-cell function (HOMA-β) index.
Improved lipid profiles by reducing total cholesterol (T-CHO), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels, while increasing high-density lipoprotein cholesterol (HDL-C) levels.
Reversed T2D-induced loss of skeletal muscle mass (improved indexes of extensor digitorum longus, tibialis anterior, soleus, gastrocnemius, and quadriceps muscles) and protected against skeletal muscle fiber atrophy.
Elevated glycogen synthesis in skeletal muscle, restored insulin-stimulated phosphorylation of IRS-1 and Akt in skeletal muscle, and downregulated PTP1B protein expression in skeletal muscle (the 25 mg/kg dose returned PTP1B expression to normal levels).
The 25 mg/kg dose reduced liver and kidney indexes, attenuated liver steatosis and renal tubule vacuolation, and decreased alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, with no observed toxicity in normal mice.
Animal Model: C57BL/6 J (male, 6-8 weeks old, 20-22 g, myocardial ischemia-reperfusion injury model via left anterior descending coronary artery ligation for 30 minutes followed by reperfusion; some groups received tail vein injection of AV-TGR5, AV-sh-TGR5, or negative control AAV9 3 weeks prior to injury)
Dosage: 50 mg/kg; 100 mg/kg; 200 mg/kg
Administration: i.p.; single dose 3 h pre-ligation
Result: Increased LVDP, +dp/dtmax, and −dp/dtmax, and decreased LVEDP dose-dependently compared to MIRI controls.
Reduced serum CK-MB and LDH levels, and reduced myocardial infarct size dose-dependently compared to MIRI controls.
Preserved myocardial fiber structure, reduced inflammatory cell infiltration, hemorrhage, edema, and necrosis; reduced myocardial fibrosis area and cardiomyocyte apoptosis rate dose-dependently compared to MIRI controls.
Reduced cleaved caspase 3 and Bax protein levels, and increased Bcl-2 protein levels compared to MIRI controls.
Reduced myocardial ROS, serum MDA, and serum LPO levels, and increased serum SOD levels dose-dependently compared to MIRI controls.
Reduced mitochondrial damage rate, improved mitochondrial structure, and reduced mitochondrial swelling and vacuolar degeneration dose-dependently compared to MIRI controls.
Increased myocardial TGR5 and p-AMPK protein levels dose-dependently compared to MIRI controls.
When combined with 100 mg/kg methyl rosmarinate, TGR5 overexpression further enhanced cardiac function, reduced myocardial injury markers, infarct size, pathological damage, oxidative stress, and mitochondrial damage, and further increased TGR5 and p-AMPK levels compared to methyl rosmarinate alone.
TGR5 knockdown reversed the beneficial effects of methyl rosmarinate, reducing cardiac function, increasing injury markers, pathological damage, oxidative stress, and mitochondrial damage, and decreasing TGR5 and p-AMPK levels compared to methyl rosmarinate alone.
性状 固体
颜色 White to light yellow

化学信息

分子量 374.34
分子式 C19H18O8
CAS No. 99353-00-1

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 10 mg/mL (26.71 mM), Solution.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.34 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (267.14 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.6714 mL13.3568 mL26.7137 mL66.7842 mL
5 mM0.5343 mL2.6714 mL5.3427 mL13.3568 mL
10 mM0.2671 mL1.3357 mL2.6714 mL6.6784 mL
15 mM0.1781 mL0.8905 mL1.7809 mL4.4523 mL
20 mM0.1336 mL0.6678 mL1.3357 mL3.3392 mL
25 mM0.1069 mL0.5343 mL1.0685 mL2.6714 mL
30 mM0.0890 mL0.4452 mL0.8905 mL2.2261 mL
40 mM0.0668 mL0.3339 mL0.6678 mL1.6696 mL
50 mM0.0534 mL0.2671 mL0.5343 mL1.3357 mL
60 mM0.0445 mL0.2226 mL0.4452 mL1.1131 mL
80 mM0.0334 mL0.1670 mL0.3339 mL0.8348 mL
100 mM0.0267 mL0.1336 mL0.2671 mL0.6678 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

Methyl rosmarinate 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础